Phase 2 N=23 Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Primary: Complete Remission (CR) — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Efficacy of Warming Device During Surgery
Surgery
Primary: The Rate of Core Rewarming Over the Range From 35°C to 37°C. — .24; .49 degrees Celcius / hr — p=0.91
Phase 2 N=43 A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
Anemia, Aplastic · Anemia, Hypoplastic · Thrombocytopenia
Primary: The Portion of Drug Responders as Defined by Hematologic Improvements — 17 Participants
Phase 1 N=27 Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Recommended Dose of PDX Given With a Fixed Dose of 5-FU — 148 mg per meter square
Phase 1 N=15 A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
Osteoporosis, Postmenopausal
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Blosozumab — 59.8 picomoles per milliliter
N/A N=75 Use of Insulin Glargine to Treat Diabetic Ketoacidosis
Diabetic Ketoacidosis
Primary: Time of Acidosis Correction
N/A N=506 ActiveStep Comparative Effectiveness Trial
Gait Disorders
Primary: Number of Subjects Reporting Any Fall — 60; 77 Participants
N/A N=133 Selenium and Immune Function
Healthy
Primary: Cellular and Humoral Immune Response — 0.29; 0.34; 0.34; 0.29 umol/min — p=<0.05
N/A N=101 Evaluation of Radiesse® Dermal Filler for Hand Rejuvenation
Aging Hands
Primary: Mean Change on Busso Hand Volume Severity Scale (BHVSS), by Hand — 2.54; 2.44; 1.72; 2.44 units on a scale — p=< 0.0001
Phase 2 N=184 Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Annual Rate of Moderate and Severe Exacerbations of COPD — 0.84; 0.88 Exacerbations per participant per year
Phase 3 N=275 Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
HIV-1 Infection
Primary: Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24 — 93.4; 97.8; 96.6 percentage of participants — p=0.15
Phase 3 N=28 Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents
Anaemia
Primary: Change From Baseline in Hgb at Week 4 — 0.79 G/dL
Phase 4 N=276 To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
Opioid Induced Constipation
Primary: Patient Reported Preference for Movantik or PEG 3350 for Opioid-induced Constipation (OIC) Treatment — 124; 118; 4 Participants
N/A N=60 Playware Technology for Balance Training
Accidental Falls
Primary: Change From Baseline in Test Score of 6 Minute Walking Test at Week 14. — 1.07; 0.568 m
N/A N=228 Analysis of Revascularization in Ischemic Stroke With EmboTrap
Stroke · Ischemia
Primary: Successful Revascularization Measured Using Modified Thrombolysis in Cerebrovascular Infarction (mTICI Inclusive of the 2c Rating) — 182 Participants